Pear Therapeutics, Inc. announced that the Ohio Department of Mental Health and Addiction Services (OhioMHAS) and RecoveryOhio are providing access to Pear’s FDA-authorized prescription digital therapeutics (PDTs) reSET® and reSET-O® for the treatment of substance use disorder (SUD) and opioid use disorder (OUD), respectively. Eligible consumers will be prescribed and treated with reSET or reSET-O to help communities throughout Ohio fight addiction. OhioMHAS will make reSET and reSET-O available to participating providers in a variety of outpatient treatment settings including opioid treatment programs that also administer transmucosal buprenorphine to prescribe and treat consumers in the state of Ohio.
Funding for the Pear PDTs is provided by the State Opioid Response (SOR) 2.0 grant, administered by OhioMHAS. The SOR 2.0 grant is part of the U.S. Department of Health and Human Services’ Substance Abuse and Mental Health Services Administration (SAMHSA) SOR grant program for people in need of prevention, treatment, and recovery support for opioid use disorder.
Pear was awarded a grant to provide reSET and reSET-O under the ‘Use of Innovation’ program that supports technology and innovation advancements in Ohio’s behavioral health care delivery system to support Ohioans on their recovery journeys. Ohio marks the third SOR grant awarded to Pear in 2021, with other SOR grants awarded by Indiana and Kentucky.
reSET and reSET-O have been tested in real-world use and randomized controlled trials, with results published in peer-reviewed medical journals. Both products, which are adjunctive to outpatient counselling, provide users with algorithm-driven cognitive behavioral therapy, fluency training, and contingency management, while clinical professionals receive access to clinical dashboards to inform in-office and tele visits. reSET is used as a monotherapy for consumers 18 years of age or older with addiction disorder and reSET-O is used in combination with transmucosal buprenorphine for consumers 18 years of age or older with opioid use disorder.
Pear Therapeutics is the leader in prescription digital therapeutics, or PDTs. Pear aims to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for consumers, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from FDA. Pear’s lead product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid medication addiction, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst™ for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program.
This was reported by Pear Therapeutics on April 22, 2021.
Contact information: Meara Murphy, Director, Corporate Communications, Pear Therapeutics, 201 Mission Street, San Francisco, California 94105; Email: email@example.com; Website: www.peartherapeutics.com.